World Health Organization. Health topics, Hepatitia. 2023. https://www.who.int/zh/health-topics/hepatitis#tab=tab_1,2023. Accessed 1 Jun 2023.

Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.

Article  PubMed  Google Scholar 

Tang LSY, Covert E, Wilson E, et al. Chronic hepatitis B infection: a review. JAMA. 2018;319(17):1802–13.

Article  CAS  PubMed  Google Scholar 

Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38.

Article  PubMed  Google Scholar 

Roberts LR. Untreated chronic hepatitis B is associated with a higher risk of extrahepatic malignancies. J Clin Oncol. 2022;40(29):3357–60.

Article  PubMed  Google Scholar 

Forbes C, Lavoie L, Satram S, et al. Global importance of new treatment strategies to efforts to control hepatitis B virus. Expert Rev Anti Infect Ther. 2023;21(8):847–62. https://doi.org/10.1080/14787210.2023.2225771.

Article  CAS  PubMed  Google Scholar 

National Health Commission of the People's Republic of China. 2021 China Health Care Statistics Yearbook. 2022. http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/304a301bfdb444afbf94b1a6c7f83bca.shtml. Accessed 1 Jun 2023.

Younossi ZM, Wong G, Anstee QM, et al. The global burden of liver disease. Clin Gastroenterol Hepatol. 2023;21(8):1978–91.

Article  PubMed  Google Scholar 

Wan YM, Wang FZ, Zhang GM, et al. Risk of hepatitis B infection and burden of disease in adults. China Vaccine Immunity. 2019;25(05):611–6. https://doi.org/10.19914/j.cjvi.2019.05.027.

Article  Google Scholar 

Yao LX, Lin S, Huang JF, et al. Analysis and prediction of the burden of disease of viral hepatitis B-related diseases in China from 1990 to 2030. Chin J Schistosomiasis Control. 2023;35(05):464–75+496. https://doi.org/10.16250/j.32.1374.2023068.

Article  CAS  Google Scholar 

Zhang S, Ma Q, Liang S, et al. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. J Viral Hepatitis. 2016;23(3):202–10.

Article  CAS  Google Scholar 

Yang N, Bertoletti A. Advances in therapeutics for chronic hepatitis B. Hepatol Int. 2016;10(2):277–85.

Article  PubMed  Google Scholar 

Kim JH, Jung SW, Byun SS, et al. Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice. Int J Clin Pharm. 2015;37(6):1228–34. https://doi.org/10.1007/s11096-015-0193-1.

Article  CAS  PubMed  Google Scholar 

Lu Q. Analysis of the use of nucleoside (acid) analogues anti-hepatitis B virus drugs in the Third Hospital Affiliated to Nantong University from 2017–2019. J Clin Ration Drug Use. 2020;13(33):17–20+24.

Google Scholar 

Rupasinghe D, Choi JY, Kumarasamy N, et al. Viral hepatitis and the cascade of care among people living with HIV in the Asia-Pacific. HIV Med. 2022;23(9):959–68. https://doi.org/10.1111/hiv.13280.

Article  CAS  PubMed  Google Scholar 

Stockdale AJ, Meiring JE, Shawa IT, et al. Hepatitis B vaccination impact and the unmet need for antiviral treatment in Blantyre, Malawi. J Infect Dis. 2022;226(5):871–80. https://doi.org/10.1093/infdis/jiab562.

Article  PubMed  Google Scholar 

Zhu Y, Xu X, Fang W, et al. Availability, cost and affordability of selected antibiotics and antiviral medicines against infectious diseases from 2013 to 2019 in Nanjing, China. Trop Med Int Health. 2021;26(5):518–29.

Article  PubMed  Google Scholar 

Duong MH, Moles RJ, Chaar B, et al. Stakeholder perspectives on the challenges surrounding management and supply of essential medicines. Int J Clin Pharm. 2019;41(5):1210–9. https://doi.org/10.1007/s11096-019-00889-1.

Article  PubMed  Google Scholar 

Qi XY, Li ZR, Hao ZY. Analysis of the impact of the centralised procurement policy of state-organised drugs on the clinical application of selected ganciclovir and entecavir based on the interrupted time series method. China Pharm Ind. 2023;32(17):9–12.

Google Scholar 

Yuan J, Lu ZK, Xiong X, et al. Impact of national volume-based procurement on the procurement volumes and spending for antiviral medications of hepatitis B virus. Front Pharmacol. 2022;13:842944. https://doi.org/10.3389/fphar.2022.842944.

Article  CAS  PubMed  PubMed Central  Google Scholar 

World Health Organization. WHO model lists of essential medicines. 2023. http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed 22 Aug 2023.

Central Government of the People’s Republic of China, Departmental documents of the State Council. National Health Insurance Bureau Ministry of Human Resources and Social Security on the Issuance of the National Catalogue of Medicines for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (2022). https://www.gov.cn/zhengce/zhengceku/2023-01/18/content_5737840.htm. Accessed 22 Aug 2023.

Chinese Medical Association Hepatology Branch, Chinese Medical Association Infectious Diseases Branch. Guidelines for the prevention and treatment of chronic hepatitis B. Chin J Infect Dis. 2023;41(1):3–28.

Google Scholar 

Sun X, Wei J, Yao Y, et al. Availability, prices and affordability of essential medicines for children: a cross-sectional survey in Jiangsu Province, China. BMJ Open. 2018;8(10):e023646.

Article  PubMed  PubMed Central  Google Scholar 

Gong S, Cai H, Ding Y, et al. The availability, price and affordability of antidiabetic drugs in Hubei province, China. Health Policy Plan. 2018;33(8):937–47.

Article  PubMed  Google Scholar 

Leucht S, Samara M, Heres S, et al. Dose equivalents for antipsychotic drugs: the DDD method. Schizophrenia Bull. 2016;42(suppl_1):S90–4.

Article  Google Scholar 

World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index 2023. 2023. https://www.whocc.no/atc_ddd_index/. Accessed 23 Aug 2023.

Jiangsu Medical Protection Bureau Drugs and Medical Consumables Sunshine Purchasing Service Network, Volume-based drug list. http://ybj.jiangsu.gov.cn/col/col86465/index.html. Assessed 31 Oct 2023.

Mu Y, Song K, Song Y. A cross-sectional study of price and affordability of drugs for rare diseases in Shandong Province, China. Int J Environ Res Public Health. 2022;19(20):13319.

Article  PubMed  PubMed Central  Google Scholar 

Jiangsu Provincial People’s Government. Jiangsu’s per capita disposable income of 49,862 yuan in 2022 higher than the national average. 2023. http://www.jiangsu.gov.cn/art/2023/2/9/art_84322_10745174.html. Assessed 13 June 2023.

Charlton MR, Alam A, Shukla A, et al. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol. 2020;55(9):811–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Z, Jin Q, Zhang Y, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021;54(9):1134–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis [published correction appears in Lancet. 2009 Feb 21;373(9664):632]. Lancet. 2009;373(9659):240–9.

Article  CAS  PubMed  Google Scholar 

Hogerzeil HV, Liberman J, Wirtz VJ, et al. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. Lancet. 2013;381(9867):680–9.

Article  PubMed  Google Scholar 

Yuan J, Lu ZK, Xiong X, Jiang B. Lowering drug prices and enhancing pharmaceutical afordability: an analysis of the national volume-based procurement (NVBP) effect in China. BMJ Glob Health. 2021;6(9):e005519.

Article  PubMed  PubMed Central  Google Scholar 

Zhu Y, Xu X, Fang W, et al. Availability, cost and affordability of selected antibiotics and antiviral medicines against infectious diseases from 2013 to 2019 in Nanjing, China. Trop Med Int Health. 2021;26(5):518–29. https://doi.org/10.1111/tmi.13559.

Article  PubMed  Google Scholar 

Wang X, He X, Zhang P, et al. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis. Int J Equity Health. 2023;22(1):200. https://doi.org/10.1186/s12939-023-02006-1.

Article  PubMed  PubMed Central  Google Scholar 

The Latest! Summary of outpatient reimbursement policies for employees’ health insurance in 13 cities in Jiangsu province out. In Jiangsu Pharmaceutical Business Association, Wechat public account. 2023. https://mp.weixin.qq.com/s/czl5ibPhPAgLrzzS9XzC5g. Accessed 23 Aug 2023.

Jiangsu Province to start the residents of medical insurance contributions: what standards, how to pay, outpatient can be reimbursed how much money? In Post-90s Coalition, Wechat public account. 2023. https://mp.weixin.qq.com/s/cqoZKq1Enuq0Ztuz9hwHsw. Accessed 1 Nov 2023.

Trouiller P, Torreele E, Olliaro P, et al. Drugs for neglected diseases: a failure of the market and a public health failure? Trop Med Int Health. 2001;6(11):945–51.

Article  CAS  PubMed  Google Scholar 

Armstrong-Hough M, Sharma S, Kishore SP, et al. Variation in the availability and cost of essential medicines for non-communicable diseases in Uganda: a descriptive time series analysis. PloS One. 2020;15(12):e0241555.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quinn EK, Massey PD, Speare R. Communicable diseases in rural and remote Australia: the need for improved understanding and action. Rural Remote Health. 2015;15(3):3371.

PubMed  Google Scholar 

Si L, Chen M, Palmer AJ. Has equity in government subsidy on healthcare improved in China? Evidence from the China’s National Health Services Survey. Int J Equity Health. 2017;16(1):6. https://doi.org/10.1186/s12939-017-0516-z.

Article  PubMed  PubMed Central  Google Scholar 

Ozaras R, Corti G, Ruta S, et al. Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. Clin Microbiol Infect. 2015;21(11):1027–32.

Article  CAS  PubMed  Google Scholar